But as we have been saying - The current fundamentals are doing...

But as we have been saying - The current fundamentals are doing nothing but acting as a trigger for the bigger fish to mess with the SP.

We all think LDX will be a great price at some stage, however, currently, the news to market is not achieving the outcome stockholders want. There is "potential" with some of the current deals, but nothing to validate that potential.

Hologic as example gave Doug a get out of jail with the IP deal they struck. If they didn't strike that, we wouldn't even be talking right now. Without BARDA coming into this, the projection for cash balance to fund the quarters would run out before CLIA waiver study finish. Without these 2 deals, they would be relying on the servicing revenue and barely staying afloat given the cash burn.

Doug and co have been making deals to keep them floating: lease back and sale of plant equipment to Hologic. Hologic IP deal, BARDA award.

Annual services revenue has remained steady since IPO. But the growth in the company hasn't been achieved. One would even say growth has remained flat given when the company IPO'd they had 3-6 products to release and the same revenue coming in.

Now, they have 2 products currently, a potential third in the sexual health range and the same revenue since IPO.

Febridx needs to crank it up in revenue this quarter to see any reasonable growth in the SP back to pre PVM sell off.